Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Lin Wang, Dan Wang, Olmo Sonzogni, et al.
Cell Reports (2022) Vol. 41, Iss. 2, pp. 111462-111462
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Savas, Balaji Virassamy, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 554-577
Closed Access | Times Cited: 46
Mass spectrometry imaging methods for visualizing tumor heterogeneity
Kyle D. Duncan, Helena Pětrošová, Julian J. Lum, et al.
Current Opinion in Biotechnology (2024) Vol. 86, pp. 103068-103068
Open Access | Times Cited: 8
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Fan Guan, Ruixuan Wang, Zhenjie Yi, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Natural product/diet-based regulation of macrophage polarization: Implications in treatment of inflammatory-related diseases and cancer
Milad Ashrafizadeh, Amir Reza Aref, Gautam Sethi, et al.
The Journal of Nutritional Biochemistry (2024) Vol. 130, pp. 109647-109647
Closed Access | Times Cited: 6
Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors
Gyöngyvér Szentmártoni, Dorottya Mühl, Renata Csanda, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 593-593
Open Access | Times Cited: 5
Targeting tumor-associated macrophages to reverse antitumor drug resistance
Li Sheng, Jiyao Sheng, Dan Zhang, et al.
Aging (2024) Vol. 16, Iss. 11, pp. 10165-10196
Open Access | Times Cited: 5
The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation
Petra Molnár, Máté Á. Demény, Beáta Várkonyi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Research progress on the role of reactive oxygen species in the initiation, development and treatment of breast cancer
Jing Zhong, Yan Tang
Progress in Biophysics and Molecular Biology (2024) Vol. 188, pp. 1-18
Closed Access | Times Cited: 4
PARP14 Contributes to the Development of the Tumor-Associated Macrophage Phenotype
Isotta Sturniolo, Csongor Váróczy, Zsolt Regdon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3601-3601
Open Access | Times Cited: 4
Leveraging Diverse Cell-Death Patterns to Decipher the Interactive Relation of Unfavorable Outcome and Tumor Microenvironment in Breast Cancer
Yue Li, Ting Ding, Tong Zhang, et al.
Bioengineering (2025) Vol. 12, Iss. 4, pp. 420-420
Open Access
PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors
Yangyang Liu, Rui Xue, Xixi Duan, et al.
Life Sciences (2023) Vol. 326, pp. 121790-121790
Closed Access | Times Cited: 9
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
Synnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 9
TRIM25-mediated XRCC1 ubiquitination accelerates atherosclerosis by inducing macrophage M1 polarization and programmed death
Hongxian Wu, Wei Gao, Yuanji Ma, et al.
Inflammation Research (2024) Vol. 73, Iss. 9, pp. 1445-1458
Closed Access | Times Cited: 3
PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages
Diego Vinicius Santinelli Pestana, Elena Aïkawa, Sasha A. Singh, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 964-964
Open Access | Times Cited: 7
Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation
Flurina Böhi, Michael O. Hottiger
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1617-1617
Open Access | Times Cited: 2
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Aurélie Moniot, Christophe Schneider, Laure Chardin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Methylation and Transcriptomic Profiling Reveals Short Term and Long Term Regulatory Responses in Polarized Macrophages
Giorgia Migliaccio, Jack Morikka, Giusy del Giudice, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 25, pp. 143-152
Open Access | Times Cited: 2
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
Felipe Batalini, Russell W. Madison, Ethan S. Sokol, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 4
Unveiling the neuroprotection effects of Volvalerenic acid A: Mitochondrial fusion induction via IDO1-mediated Stat3-Opa1 signaling pathway
Shanchun Ge, Lei Wang, Chang Jin, et al.
Phytomedicine (2024) Vol. 129, pp. 155555-155555
Closed Access | Times Cited: 1
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?
Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
LHFPL2 Serves as a Potential Biomarker for M2 Polarization of Macrophages in Renal Cell Carcinoma
Xiaocheng Gong, Yunfei Liu, Qian Zhang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6707-6707
Open Access | Times Cited: 1
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin Zheng, Qin Zhou, Jianan Cheng, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 4, pp. 617-648
Closed Access | Times Cited: 3
Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers
Geoffrey I. Shapiro, Suzanne Barry
Cancer treatment and research (2023), pp. 207-221
Closed Access | Times Cited: 2
Implicating the cholecystokinin B receptor in liver stem cell oncogenesis
Martha D. Gay, Jack C. Drda, Wenqiang Chen, et al.
AJP Gastrointestinal and Liver Physiology (2024) Vol. 326, Iss. 3, pp. G291-G309
Open Access
Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP-inhibition
Siddhartha Mukherjee, Angela Rita Elia, Cindy Garda, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top